# IL-6 inhibition with clazakizumab in patients receiving maintenance dialysis: a randomized phase 2b trial

*PRI Rank #10 · Topics and Trends in Most Cited Dialysis and Renal Disease Management Papers, Class of 2026*

*Canonical URL: https://pri.pepkio.com/top-papers/dialysis-and-renal-disease-management/2026/rank-10*

| Field | Value |
| --- | --- |
| Rank | #10 |
| 18m citations | 52 |
| Journal | Nature Medicine |
| Year | 2024 |
| DOI | 10.1038/s41591-024-03043-1 |
| Corresponding authors | Glenn M. Chertow |
| Institution | Stanford University, United States |

**Ranking page:** [Topics and Trends in Most Cited Dialysis and Renal Disease Management Papers, Class of 2026](https://pri.pepkio.com/top-papers/dialysis-and-renal-disease-management/2026)

**Paper link:** [10.1038/s41591-024-03043-1](https://doi.org/10.1038/s41591-024-03043-1)

## Topics

Clazakizumab · IL-6 inhibition · Clazakizumab · Dialysis · High-sensitivity C-reactive protein · phase 2b dose-finding study · geometric mean ratio primary endpoint · serum fibrinogen reduction · serum amyloid A · secretory phospholipase A2 · lipoprotein(a) · serum albumin increase · cardiovascular risk in dialysis patients · inflammatory biomarkers · dose-ranging (2.5 mg, 5 mg, 10 mg) · thrombocytopenia safety monitoring · neutropenia safety monitoring · serious infection risk · diabetes and cardiovascular comorbidity in dialysis population · NCT05485961

## Cite this ranking

```
Pepkio Research Index (PRI). Topics and Trends in Most Cited Dialysis and Renal Disease Management Papers, Class of 2026. https://pri.pepkio.com/top-papers/dialysis-and-renal-disease-management/2026. Accessed 2026-07-14.

Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459
```